Skip Navigation

COVID-19 Update

Due to interest in the COVID-19 vaccines, we are experiencing an extremely high call volume. Please understand that our phone lines must be clear for urgent medical care needs. We are unable to accept phone calls to schedule COVID-19 vaccinations at this time. When this changes, we will update this website. Our vaccine supply remains limited. Read all COVID-19 Vaccine Information.

Patient Care Options | Visitor Guidelines | Coronavirus Information | Self-Checker | Get Email Alerts

Dipali Sharma, M.S., Ph.D.

Headshot of Dipali Sharma
  • Professor of Oncology

Research Interests

Signaling Mechanisms; Bioactive Food Components; Novel Therapeutics; Tamoxifen Resistance; Metastasis; Adipocytokines; Obesity-Cancer Connection; Breast Cancer more



  • Professor of Oncology

Departments / Divisions

  • Oncology - Division of Women's Malignancies

Centers & Institutes



  • Ph.D.; College of Medicine Sci - University of Delhi - New Delhi - Delhi - (India) (1999)
  • B.S.; University of Delhi (India) (1991)
  • M.S.; University of Delhi (India) (1993)
  • M.S.; University of Delhi (India) (1994)

Research & Publications

Research Summary

The research in Sharma lab is focused in two main areas:

  1. Investigating the molecular links between obesity and cancer, emphasizing aspects that have potential clinical significance and development of novel therapeutics. To get to the bottom of obesity-cancer connection, her lab is exploring the genes, molecules, hormones and cellular processes that could cause and promote cancer in obese people. Using various physiologically relevant mouse models and cell lines, their aim is to find molecular targets that can be effectively targeted by small molecule inhibitors as well as bioactive food components. Their overall goal is to understand the molecular networks by which obesity affects carcinogenesis and discover novel agents to effectively disrupt obesity-cancer axis.
  2. Investigating the molecular mechanisms by which breast cancers acquire resistance to endocrine therapy and develop new treatment strategies to overcome this resistance. In this research, they combine molecular and genetic approaches to focus on the crosstalk between growth factor pathways and coregulator proteins. The goal is to understand the mechanistic links, define molecular profiles that can be used to predict development of endocrine resistance and develop targeted therapies.

Selected Publications

Sharma, D., and Fondell, J. D. Ordered recruitment of histone aceyltransferases and TRAP/Mediator complex to thyroid hormone responsive promoters in vivo. Proc. Natl. Acad. Sci., USA, 99(12): 7934-7939, 2002.

Sharma, D., Saxena, N. K., Davidson, N. E., and Vertino, P. M. Restoration of tamoxifen sensitivity in ER-negative breast cancer cells. Tamoxifen-bound reactivated estrogen receptor recruits distinct chromatin modifying corepressors complexes. Cancer Research, 66: 6370-6378, 2006.

Sharma, D., Blum, J., Yang, X., Beaulieu, N., Macleod, A. R., and Davidson, N. E. Release of Methyl CpG Binding Proteins and Histone Deacetylase 1 from the Estrogen Receptor Alpha (ER) Promoter upon Reactivation in ER-negative Human Breast Cancer Cells. Mol Endocrinol., 19 (7): 1740-1751, 2005.

Sharma, D., Wang, J., Fu, P. P., Sharma, S., Nagalingam, A., Mells, J., Handy, J., Page, A. J., Cohen, C., Anania, F. A., and Saxena, N. K. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology, 52(5): 1713-1722, 2010.

Nagalingam, A., Kuppusamy, P., Singh, S. V., Sharma, D* and Saxena, N. K. Mechanistic elucidation of the antitumor properties of Withaferin A in breast cancer. Cancer Research, 74(9):2617-29, 2014.

Contact for Research Inquiries

Phone: 410-955-1345
Is this you? Edit Profile
back to top button